Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy
Aim - radiopeptide therapy with beta emitter labeled ¹⁷⁷Lu/⁹⁰Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting ²¹³Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment response have been recognized and tumor-shrinkage a...
Saved in:
| Published in: | Experimental Oncology |
|---|---|
| Date: | 2013 |
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2013
|
| Subjects: | |
| Online Access: | https://nasplib.isofts.kiev.ua/handle/123456789/145224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Journal Title: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Cite this: | Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy / F.L. Giesel, P. Flechsig, T. Kuder, L. Schwartz, S. Wulfert, C. Zechmann, F. Bruchertseifer, U. Haberkorn, C. Kratochwil // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 122-126. — Бібліогр.: 9 назв. — англ. |
Institution
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1862542624059031552 |
|---|---|
| author | Giesel, F.L. Flechsig P. Kuder T. Schwartz L. Wulfert S. Zechmann C. Bruchertseifer F. Haberkorn U. Kratochwil C. |
| author_facet | Giesel, F.L. Flechsig P. Kuder T. Schwartz L. Wulfert S. Zechmann C. Bruchertseifer F. Haberkorn U. Kratochwil C. |
| citation_txt | Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy / F.L. Giesel, P. Flechsig, T. Kuder, L. Schwartz, S. Wulfert, C. Zechmann, F. Bruchertseifer, U. Haberkorn, C. Kratochwil // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 122-126. — Бібліогр.: 9 назв. — англ. |
| collection | DSpace DC |
| container_title | Experimental Oncology |
| description | Aim - radiopeptide therapy with beta emitter labeled ¹⁷⁷Lu/⁹⁰Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting ²¹³Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment response have been recognized and tumor-shrinkage after radiation therapy appears slowly. In some solid tumors a decline in tumor perfusion was found predictive of final treatment response but the gold standard multiphase computed tomography (CT) has a high radiation burden. Therefore we evaluated the ability of contrast-enhanced ultrasound (CEUS) to evaluate tumor perfusion as a response criteria. 14 patients with hepatic neuroendocrine tumor (NET) metastases were enrolled in the retrospective study. Eleven patients were treated with beta-emitting ¹⁷⁷Lu/⁹⁰Y-DOTATOC, either intravenous (i.v.) (n = 5) or intra-arterial (i.a.) (n = 6) and three patients received alpha-emitting ²¹³Bi-DOTATOC (i.a.). CEUS and contrast-enhanced CT (CE-CT) were performed before and 3 months after treatment. CE-CT and CEUS presented comparable results in the baseline study and in the assessment of perfusion changes due to the different treatment regimes. A therapy related decrease in tumor perfusion is an early predictor of longterm morphologic response. Conclusion: CEUS is available and radiation free technique which showed comparable results for perfusion and diameter of liver metastases compared to CE-CT. Intensity reduction in an arterial phase CEUS can be seen as a positive sign indicating long term tumor response to treatment. Therefore CEUS may be considered as an imaging modality for monitoring early treatment after focal alpha and beta targeted therapy. Key Words: contrast-enhanced ultrasound, radionuclide therapy, treatment response, DOTATOC PET/CT.
|
| first_indexed | 2025-11-24T20:37:34Z |
| format | Article |
| fulltext | |
| id | nasplib_isofts_kiev_ua-123456789-145224 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1812-9269 |
| language | English |
| last_indexed | 2025-11-24T20:37:34Z |
| publishDate | 2013 |
| publisher | Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| record_format | dspace |
| spelling | Giesel, F.L. Flechsig P. Kuder T. Schwartz L. Wulfert S. Zechmann C. Bruchertseifer F. Haberkorn U. Kratochwil C. 2019-01-19T16:07:01Z 2019-01-19T16:07:01Z 2013 Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy / F.L. Giesel, P. Flechsig, T. Kuder, L. Schwartz, S. Wulfert, C. Zechmann, F. Bruchertseifer, U. Haberkorn, C. Kratochwil // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 122-126. — Бібліогр.: 9 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/145224 Aim - radiopeptide therapy with beta emitter labeled ¹⁷⁷Lu/⁹⁰Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting ²¹³Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment response have been recognized and tumor-shrinkage after radiation therapy appears slowly. In some solid tumors a decline in tumor perfusion was found predictive of final treatment response but the gold standard multiphase computed tomography (CT) has a high radiation burden. Therefore we evaluated the ability of contrast-enhanced ultrasound (CEUS) to evaluate tumor perfusion as a response criteria. 14 patients with hepatic neuroendocrine tumor (NET) metastases were enrolled in the retrospective study. Eleven patients were treated with beta-emitting ¹⁷⁷Lu/⁹⁰Y-DOTATOC, either intravenous (i.v.) (n = 5) or intra-arterial (i.a.) (n = 6) and three patients received alpha-emitting ²¹³Bi-DOTATOC (i.a.). CEUS and contrast-enhanced CT (CE-CT) were performed before and 3 months after treatment. CE-CT and CEUS presented comparable results in the baseline study and in the assessment of perfusion changes due to the different treatment regimes. A therapy related decrease in tumor perfusion is an early predictor of longterm morphologic response. Conclusion: CEUS is available and radiation free technique which showed comparable results for perfusion and diameter of liver metastases compared to CE-CT. Intensity reduction in an arterial phase CEUS can be seen as a positive sign indicating long term tumor response to treatment. Therefore CEUS may be considered as an imaging modality for monitoring early treatment after focal alpha and beta targeted therapy. Key Words: contrast-enhanced ultrasound, radionuclide therapy, treatment response, DOTATOC PET/CT. en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Original contributions Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy Article published earlier |
| spellingShingle | Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy Giesel, F.L. Flechsig P. Kuder T. Schwartz L. Wulfert S. Zechmann C. Bruchertseifer F. Haberkorn U. Kratochwil C. Original contributions |
| title | Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy |
| title_full | Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy |
| title_fullStr | Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy |
| title_full_unstemmed | Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy |
| title_short | Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy |
| title_sort | contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷lu/⁹⁰y-dotatoc and ²¹³bi-dotatoc radiopeptide therapy |
| topic | Original contributions |
| topic_facet | Original contributions |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/145224 |
| work_keys_str_mv | AT gieselfl contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy AT flechsigp contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy AT kudert contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy AT schwartzl contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy AT wulferts contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy AT zechmannc contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy AT bruchertseiferf contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy AT haberkornu contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy AT kratochwilc contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy |